Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AXIM BIOTECHNOLOGIES, INC.AXIM · Entity 9689 | Director · CEO/Secretary · 10% owner | December 31, 2016 | February 15, 2017 |
| Incannex Healthcare Inc.IXHL · Entity 7349 | Director | November 14, 2025 | November 14, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AXIM BIOTECHNOLOGIES, INC.
Report date December 31, 2016 · Filed February 15, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,002,000 |
Reported balance
After 2016-11-21 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2016-11-21 · Grant · Acquired 250,000 · Balance 3,002,000 F1: Mr. Anastassov is an affiliate and control person of Sanammad Foundation which holds 3,626,706 shares of common stock. Mr. Anastassov is an affiliate and control person of Sanammad Foundation USA which holds 14,613,650 shares of common stock. |
| Common StockSEC Table I · non-derivative | Direct | 3,002,000 |
Reported balance
After 2016-11-21 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2016-11-21 · Grant · Acquired 2,000,000 · Balance 3,002,000 F1: Mr. Anastassov is an affiliate and control person of Sanammad Foundation which holds 3,626,706 shares of common stock. Mr. Anastassov is an affiliate and control person of Sanammad Foundation USA which holds 14,613,650 shares of common stock. |
| Preferred StockSEC Table I · non-derivative | IndirectSee footnote 2 | 500,000 |
Reported balance
After 2016-11-21 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2016-11-21 · Grant · Acquired 500,000 · Balance 500,000 F2: Mr. Anastassov is an affiliate and control person of Sanammad Foundation which holds 500,000 shares of Series B preferred stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Mr. Anastassov is an affiliate and control person of Sanammad Foundation which holds 3,626,706 shares of common stock. Mr. Anastassov is an affiliate and control person of Sanammad Foundation USA which holds 14,613,650 shares of common stock.
F2: Mr. Anastassov is an affiliate and control person of Sanammad Foundation which holds 500,000 shares of Series B preferred stock.
Incannex Healthcare Inc.
Report date November 14, 2025 · Filed November 14, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.0001 par value per shareSEC Table I · non-derivative | Direct | 2,456,677 |
Reported balance
After 2025-11-14 transaction · row 1
1 source rowRow 1 · 2025-11-14 · Grant · Acquired 1,686,956 · Balance 2,456,677 F1: Includes the following shares of restricted stock (the "Shares") granted on November 14, 2025, under the Issuer's 2023 Equity Incentive Plan, (i) 421,739 Shares that vest in full on December 10, 2025, (ii) 421,739 Shares that vest in full on June 30, 2026, (iii) 421,739 Shares that vest in full on June 30, 2026 and (iv) 421,739 Shares that vest in full on June 30, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes the following shares of restricted stock (the "Shares") granted on November 14, 2025, under the Issuer's 2023 Equity Incentive Plan, (i) 421,739 Shares that vest in full on December 10, 2025, (ii) 421,739 Shares that vest in full on June 30, 2026, (iii) 421,739 Shares that vest in full on June 30, 2026 and (iv) 421,739 Shares that vest in full on June 30, 2027.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 14, 2025 Filed Nov 14, 2025 06:11 UTC | Incannex Healthcare Inc. IXHL · Entity 7349 | GrantCommon Stock, $0.0001 par value per share | 1,686,956 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-25-110271 · ownership.xml · nonDerivative · entry 1 Anastassov George · CIK 0001604392 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,456,677 F1 · shares: Includes the following shares of restricted stock (the "Shares") granted on November 14, 2025, under the Issuer's 2023 Equity Incentive Plan, (i) 421,739 Shares that vest in full on December 10, 2025, (ii) 421,739 Shares that vest in full on June 30, 2026, (iii) 421,739 Shares that vest in full on June 30, 2026 and (iv) 421,739 Shares that vest in full on June 30, 2027. Read SEC document |
| December 21, 2023 Filed Dec 21, 2023 20:49 UTC | Incannex Healthcare Inc. IXHL · Entity 7349 | GrantCommon Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-23-097814 · ownership.xml · nonDerivative · entry 1 Anastassov George · CIK 0001604392 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 769,721 F1 · kind: Award of restricted stock of which 25,000 shares will vest on December 31, 2023, 25,000 shares concerning the remuneration of fiscal year 2023 will vest on June 30, 2024, 25,000 shares concerning the remuneration of fiscal year 2024 will vest on June 30, 2024, and 25,000 shares will vest on June 30, 2025, based upon the Reporting Person's continuing service as director on each vesting date. Read SEC document |
| November 21, 2016 Filed Feb 15, 2017 19:20 UTC | AXIM BIOTECHNOLOGIES, INC. AXIM · Entity 9689 | GrantPreferred Stock | 500,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001078782-17-000216 · primary_doc.xml · nonDerivative · entry 3 Anastassov George · CIK 0001604392 · Director · CEO/Secretary · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote 2 Disclosed balance after: 500,000 F2 · ownership.direct: Mr. Anastassov is an affiliate and control person of Sanammad Foundation which holds 500,000 shares of Series B preferred stock. Read SEC document |
| November 21, 2016 Filed Feb 15, 2017 19:20 UTC | AXIM BIOTECHNOLOGIES, INC. AXIM · Entity 9689 | GrantCommon Stock | 2,000,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001078782-17-000216 · primary_doc.xml · nonDerivative · entry 2 Anastassov George · CIK 0001604392 · Director · CEO/Secretary · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,002,000 F1 · ownership.direct: Mr. Anastassov is an affiliate and control person of Sanammad Foundation which holds 3,626,706 shares of common stock. Mr. Anastassov is an affiliate and control person of Sanammad Foundation USA which holds 14,613,650 shares of common stock. Read SEC document |
| November 21, 2016 Filed Feb 15, 2017 19:20 UTC | AXIM BIOTECHNOLOGIES, INC. AXIM · Entity 9689 | GrantCommon Stock | 250,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001078782-17-000216 · primary_doc.xml · nonDerivative · entry 1 Anastassov George · CIK 0001604392 · Director · CEO/Secretary · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,002,000 F1 · ownership.direct: Mr. Anastassov is an affiliate and control person of Sanammad Foundation which holds 3,626,706 shares of common stock. Mr. Anastassov is an affiliate and control person of Sanammad Foundation USA which holds 14,613,650 shares of common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.